Lexaria Bioscience opened lower at $4.49, compared with its previous close of $4.64. In the last trading session, the stock traded between $4.02 and $4.44. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Lexaria Bioscience is now worth
$ 65.87
Resulting in a loss of
$ 34.13 (34.13%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.35 (-7.44%)
Day High
$4.44
Day Low
$4.02
Day Open
$4.49
Prev Close
$4.64
Volume
32,439
1W Return
5.01%
1M Return
31.23%
3M Return
-25.37%
6M Return
610.15%
1Y Return
283.48%
Fundamentals
Market Cap ($ Mn)
9
PE Ratio
-
PB Ratio
3.62
PEG Ratio
-
ROE
-177.80%
ROCE
-185.85%
EPS (TTM)
$-1.20
Investment Returns
1 Week
5.01%
1 Month
31.23%
3 Months
-25.37%
6 Months
610.15%
9 Months
573.62%
Financials
Quarterly
All values in $ Mn
0.2
Feb 25
0.2
May 25
0.2
Aug 25
0.0
Nov 25
0.0
Feb 26
0.0
May 26
Updates
21Oct
Lexaria completes enrollment in oral semaglutide pilot study
Full enrollment achieved in Human Pilot Study #7 (GLP-1-H26-7). Final arm began dosing in early October, completing by mid-November. Study compares oral DehydraTECH-semaglutide against Novo's Wegovy tablets. First multi-week evaluation of SNAC-integrated tablet and capsule formulations.
22 days ago
15Oct
Lexaria Bioscience reports 566% brain absorption gain in CBD study
DHT-CBD ALT2 formulation showed 566% higher brain absorption than reference arm. Plasma absorption for most alternative formulations was not statistically different from reference. DHT-SEMA brain concentrations were below lower limit of quantitation in this study. Lexaria filed three new patent applications based on study findings.
